As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000's recent underperformance. Amidst these dynamics, high growth tech stocks such as Shanghai Henlius Biotech stand out by leveraging innovation and adaptability to navigate economic shifts and investor expectations.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Material Group | 20.45% | 24.01% | ★★★★★★ |
Yggdrazil Group | 30.20% | 87.10% | ★★★★★★ |
Seojin SystemLtd | 35.41% | 39.86% | ★★★★★★ |
eWeLLLtd | 27.24% | 28.74% | ★★★★★★ |
Medley | 25.57% | 31.67% | ★★★★★★ |
Waystream Holding | 22.09% | 113.25% | ★★★★★★ |
Mental Health TechnologiesLtd | 25.83% | 113.12% | ★★★★★★ |
CD Projekt | 24.92% | 27.00% | ★★★★★★ |
Fine M-TecLTD | 36.52% | 131.08% | ★★★★★★ |
JNTC | 29.48% | 104.37% | ★★★★★★ |
Click here to see the full list of 1267 stocks from our High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shanghai Henlius Biotech, Inc. focuses on the research and development of biologic medicines targeting oncology, autoimmune diseases, and ophthalmic diseases, with a market cap of HK$12.96 billion.
Operations: Henlius generates revenue primarily from its pharmaceuticals segment, amounting to CN¥5.64 billion. The company is involved in the development of biologic medicines across key therapeutic areas.
Shanghai Henlius Biotech's recent advancements underscore its strategic focus on developing innovative therapies in the biotech sector. With a revenue growth of 9.8% and earnings growth forecast at 11.92% per year, the company is outpacing the Hong Kong market averages significantly, suggesting robust operational execution. Notably, its R&D efforts are pivotal, highlighted by the approval of HLX22 for phase 2 trials and HLX43 targeting PD-L1, positioning it at the forefront of cancer treatment innovations. These developments reflect a promising trajectory in addressing complex medical needs while expanding its influence in global markets through strategic product pipelines and clinical trials.
Gain insights into Shanghai Henlius Biotech's historical performance by reviewing our past performance report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Visual China Group Co., Ltd. operates as an internet media service provider both in China and internationally, with a market capitalization of CN¥21 billion.
Operations: Visual China Group Co., Ltd. generates revenue through its internet media services, serving both domestic and international markets. The company leverages digital platforms to offer a range of media content and related services, contributing to its market presence in the industry.
Visual China GroupLtd has demonstrated resilience in a challenging market, with its revenue climbing to CNY 608.03 million from CNY 574.3 million year-over-year, reflecting a growth of 5.9%. Despite a downturn in net income from CNY 122.54 million to CNY 81.69 million, the company is poised for significant earnings growth, projected at an annual rate of 28.7%. This performance is underpinned by strategic amendments to its employee stock ownership plan and by-elections of independent directors aimed at bolstering governance and innovation within the firm's operations in interactive media and services—an industry where staying ahead technologically is crucial for maintaining competitive advantage.
Gain insights into Visual China GroupLtd's past trends and performance with our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DeNA Co., Ltd. is a company that develops and operates mobile and online services globally, with a market capitalization of approximately ¥298.93 billion.
Operations: The company generates revenue primarily through its Game Business, Sports Businesses, Livestreaming Business, and Healthcare & Medical Business segments. The Game Business is the largest contributor with ¥50.20 billion in revenue, followed by the Livestreaming Business at ¥41.37 billion.
DeNA, navigating through a volatile market, is poised for significant growth with its revenue expected to rise by 4.8% annually. The company's strategic focus on R&D is evident from its substantial investment in innovation, crucial for staying competitive in the tech-driven market landscape. Despite current unprofitability, DeNA's earnings are projected to surge by 89.2% annually, underpinned by positive free cash flow and a shift towards profitability within three years. This forward-looking approach is supported by recent announcements such as the upcoming Q2 2025 results, signaling potential pivotal shifts in operational strategies and market positioning.
Understand DeNA's track record by examining our Past report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocks
Try a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。